All In Biotech

Drug Trial Radar · NCT07129382

A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of CS32582 Capsule in Adult Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Sep 18, 2027

Study completion Sep 18, 2027

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

" This study consists of two parts: Part 1 (Dose Escalation): A randomized, double-blind, placebo-controlled phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks. Part 2 (Efficacy and Safety Assessment): A randomized, double-blind, placebo-controlled evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment. The resulting data will provide preliminary evidence on the safety and efficacy profile of CS32582, informing its subsequent development strategy.

Conditions

  • Plaque Psoriasis

Interventions

  • CS32582 capsule(low dose) or matched placeboDrug

    CS32582 capsule(low dose) or matched placebo,4 weeks

  • CS32582 capsule(high dose) or matched placeboDrug

    CS32582 capsule(high dose) or matched placebo,4 weeks

  • CS32582 capsule(low dose)Drug

    CS32582 capsule(low dose),12 weeks

  • CS32582 capsule(medium dose)Drug

    CS32582 capsule(medium dose),12 weeks

  • CS32582 capsule(high dose)Drug

    CS32582 capsule(high dose),12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1:Incidence and Severity of Adverse Events (AEs)Time frame: 5 weeks
  2. Part 2:Proportion of patients achieved Psoriasis Area Severity Index (PASI) 75 at Week 12Time frame: Week 12

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Not yet recruiting

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Shiyan People's Hospital

    Shiyan, Hubei, China · Not yet recruiting

  • Shandong Provincial Hospital for Skin Diseases

    Jinan, Shandong, China · Not yet recruiting

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital )

    Xi’an, Shanxi, China · Not yet recruiting

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    Hangzhou, Zhejiang, China · Not yet recruiting

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, China · Not yet recruiting

  • The First Affliated Hospital of Wenzhou Medical University

    Wenzhou, Zhengjiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.